SOLARA ACTIVE PHARMA SCIENCES LTD Q4 RESULTS
Long term Alpha generators: 8 mid and small cap stocks from pharma and healthcare sector with an upside potential of up to 27%
After a long period of time, recently an Indian pharma company announced its intention to takeover a reasonably sized European company. This is more than just a single development, it is reflecting a change in underlying operating matrix of the pharma industry which for the last many years has been going through a period of readjustment and is now coming out of it. Not many may know that an Indian hospital chain operates a hospital in Cayman Island. The Indian healthcare and pharma sector are two spaces which probably will grow at a much faster rate than other sectors. There are both macro and micro factors which will lead to higher growth. It is faster growth which leads to generation of alpha, which ideally is what investors are seeking when taking risk in equities
Volatile phases come and go, structural tailwinds are a stronger play: 5 Indian pharma stocks with upside potential of up to 35%
There are some sectors which have witnessed something which can be called “second inning”. Which is that in the last two decades, they did very well at one point of time, then faced tons of challenges both at the business level and street and now are making a comeback. Now this comeback has a higher probability of sustaining because it is after experience of one simple thing, what a pharma company should not do when it comes to the regulatory aspect of business. Also more efficient utilisation of capital and thinking long term when it comes to moving to different markets. If the market turns volatile even more, will these stocks not correct, will the pharma not correct, but there is high probability of the out performing in terms of lesser draw down. The only risk which is company specific risk is if the company has an issue with regulator USFDA. But then nothing comes without risk in equity markets.
Sun Pharma Q1 Results: Net profit rises 40% YoY to Rs 2,836 crore, beats estimates
Sun Pharma Q1 Results: Sun Pharma reported a 40% increase in consolidated net profit to Rs 2,836 crore, surpassing estimates of Rs 2,638 crore. Revenue rose 6% YoY to Rs 12,653 crore. EBITDA grew 8% YoY to Rs 3,608 crore with margins at 28.5%. India formulation sales reached Rs 4,144 crore, up 16%, constituting 33.1% of total sales.
Tech Mahindra Q1 Results: Profit jumps 23% YoY to Rs 851 crore, misses estimates
Tech Mahindra Q1 Results: Tech Mahindra reported a 23% year-on-year growth in consolidated net profit to Rs 851 crore for the June quarter, slightly below the expected Rs 892 crore. Revenue from operations declined 1% YoY to Rs 13,005 crore. Sequentially, profit after tax rose by 28% and revenue increased by 1%.
Alpha generators in the long term: 9 mid and small cap stocks from pharma and healthcare sector with an upside potential of up to 29%
While some make it to the headlines, some don't. Two sectors, healthcare and pharma have been witnessing more mergers and acquisitions than any other sector. There is a logical reason why private equity money is flowing in these sectors. Probably these two sectors are the ones with maximum potential to grow over the next decade or so. In the case of pharma, facts are well known, right from skilled manpower to lower manufacturing costs. In the case of healthcare, there are two things: first, medical tourism, second, soft exports of medical services. Not many may know, some of the best known doctors from India fly to CIS and other countries, where the healthcare companies have their OPD. Either the patient is treated there, if possible or else he is referred to India for treatment. While it might sound impossible, given the broken healthcare system which even some of the best developed countries have, in future, Indian healthcare companies taking over global hospitals may also become a reality.
Pharma sector: Turnaround for good, 6 small and mid cap pharma stocks with upside potential of up to 32%
While it might not have been making it headline, the pharmaceutical sector or commonly called as pharma has come through a tough period due to US FDA and other factors. It has been witnessing a turnaround of sorts which has been slow but more companies are showing improvement in their performance. Also there is a process of re-rating which is quietly going on in the sector. It was large players which got the attention of tend to gain first and then it is smaller and mid sized. If one looks at the corporate announcement about approval of drugs by the US FDA or other drug regulator or any entry into new markets, a number of them are coming from mid and small companies. Given the lesson which the Indian pharma industry has learnt after its reckless approach between 2005 to 2015, there is a high probability that the sector may gain attention.
- Go To Page 1
Q1 results, FII action among 10 factors to impact D-Street mood this week
Nifty gained 1.2%, driven by IT, energy, and pharma stocks. U.S. labor data, TCS earnings, Rupee vs. Dollar, Bank Nifty, oil prices, FIIs, IPO action, and dividends will influence markets next week. Bulls maintain strength with positive sentiment and broader market participation, expecting some consolidation.
India Inc registers 501 deals valued at USD 21.4 bn in Q2 2024: Grant Thornton
Grant Thornton Bharat's Q2 2024 report shows 501 deals worth USD 21.4 billion. Despite a 28% value decrease post Reliance-Disney mega-merger, domestic investment and private equity remain strong. High-value deals (over USD 100 million) rose 58% with 30 significant deals. Political stability and policy clarity boosted traditional sectors like pharma and manufacturing, states Shanthi Vijetha.
Torrent Pharma board approves to raise Rs 5,000 crore
Torrent Pharmaceuticals, actively seeking to expand through acquisitions, has expressed interest in purchasing Mumbai-based pharmaceutical company JB Pharma, according to a report by ET on Friday.
Glenmark Pharma Q4 Results: Net loss widens to Rs 121 crore YoY
Glenmark Pharma Q4 Results: The rise in loss was on account of declining sales in the US and exceptional items. It had reported a net loss of Rs 34.5 crore in the corresponding quarter of the previous year. In FY24, Glenmark's consolidated revenue reached Rs. 11,813 crore, a 2% increase year-over-year. The company's EBITDA margin for the fiscal year was 10.1%, primarily due to a one-time impact on sales in the India business during the third quarter.
Strides Pharma Q4 Results: Pharma co reports Rs 10.4 crore net profit
Strides Pharma Science posted a net profit of Rs 10.4 crore in Q4FY24, rebounding from a loss of Rs 1 crore in the same period last year. Pre-tax profit was Rs 29.6 crore.
Strides Pharma Q4 Results: Firm posts net profit of Rs 10 crore vs loss YoY
Strides Pharma Science Ltd reported a net profit of Rs 10.44 crore in Q4 ended March 2024. The company announced Arun Kumar as Executive Chairperson. Consolidated total income was Rs 1,070.49 crore with expenses at Rs 984.21 crore. A final dividend of Rs 2.50 per equity share was recommended. FY24 revenue grew driven by US and regulated markets.
Q4 results this week: ITC, ONGC, Sun Pharma, Nykaa, Ircon International and IRFC
ITC, ONGC, IRFC, Ircon International, BHEL, BEL, Sun Pharma, Nykaa, Tata Investment Corporation, Hindalco, Ashok Leyland, and Divi's lab will be releasing their March quarter report cards this week.
Q4 results this week: Zomato, Airtel, M&M among 501 companies set to announce earnings this week
Some notable companies that will announce their earnings this week include Varun Beverages, Zomato, Airtel, Siemens, Power Finance Corp, Mahindra and Mahindra, HAL, and JSW Steel, among others. Overall, around 501 companies are set to release their quarterly numbers this week.
Stocks in news: Tata Motors, Bank of Baroda, Cipla, BPCL, Manappuram Finance
State-run BPCL on Thursday posted a 35% drop in its standalone net profit at Rs 4,224 crore in the fourth quarter, compared with Rs 6,478 crore in the last year period.
Q4 results this week: SBI, Tata Motors, L&T, Asian Paints, TVS Motor and PB Fintech
Various widely tracked companies like Tata Motors, SBI, Asian Paints, BPCL, Larsen & Toubro, Tata Power, Canara Bank, TVS Motor, Hero MotoCorp, Godrej Consumer Products, JSW Energy, Dr. Reddy's Laboratories, PB Fintech, and Bank of Baroda will be releasing their March quarter report cards this week. Here’s a list:
Axis Bank re-appoints Amitabh Chaudhry as MD & CEO for three more years, shares top 5%
Axis Bank's board approved the re-appointment of Amitabh Chaudhry as MD & CEO for three more years, subject to RBI approval, effective January 2025. Chaudhry, who joined in 2019, led HDFC Life previously. The bank also re-appointed Meena Ganesh and Gopalaraman Padmanabhan as Independent Directors. In Q4, Axis Bank reported strong profits, with concerns about deposit growth for the upcoming fiscal yea
How to trade Maruti, RIL and 4 other stocks ahead of Q4 earnings
India VIX surged 17%, prompting trading strategies for Maruti, RIL, Tata Consumer Products, Axis Bank, Bajaj Finance, and HUL. Technical analysis indicated positive market movements with RSI and stochastic indicators. Watch for Iran-Israel developments and India VIX levels at 15.
Only 39 smallcap stocks rise in double-digits as geopolitical concerns, lofty valuations weigh
Indian markets faced pressure from Middle East concerns, impacting smallcap stocks' returns. Top gainers included Moschip Technologies, Solara Active Pharma, and Dhani Services.
Buy Solara Active Pharma Sciences, target price Rs 400: Motilal Oswal
Solara Active Pharma Sciences Ltd., incorporated in the year 2017, is a Small Cap company (having a market cap of Rs 1249.61 Crore) operating in Pharmaceuticals sector.
Glenmark Pharma Q2 Results: Co posts loss on exceptional legal costs
The company posted a consolidated net loss, from continuing operations, of 2.01 billion rupees ($24.14 million) for the three months ended Sept. 30, from a profit of 1.54 billion rupees a year ago
Aurobindo Pharma Q2 Results: Net profit soars 84% to Rs 752 crore on strong overseas demand
Aurobindo Pharma on Thursday reported 84% year-on-year (YoY) rise in net profit to Rs 752 crore in the second quarter ended September 2023, led by strong sales from the US market.
Poor EHS compliance a latent risk for pharma, chemical companies
"The general level of awareness and compliance related to EHS (Environment Health & Safety) norms in case of manufacturing companies requires drastic improvement and urgent attention" said Nagaraj Krishnan, managing director, Aparajitha Corporate Services, a tech firm providing compliance solutions to over 2000 companies in India.
Sun Pharma Q2 Results: Cons profit rises 6% YoY to Rs 2,385 crore, beats estimates
Operating profit, calculated as earnings before interest, taxes, depreciation, and amortization (EBITDA), for the quarter, rose nearly 8% on year to Rs 3,179.30 crore, but operating margin contracted by 91 basis points to 26.08%. Total expenses in the quarter rose to Rs 9,695 crore, from Rs 8,625 crore a year ago.
Q2 Results Tomorrow: What to expect from Bharti Airtel, L&T, Tata Consumer?
Indian Oil Corporation, GAIL (India), Mankind Pharma, Jindal Steel & Power, Adani Total Gas, Star Health and Allied Insurance, Max Financial Services, Vedant Fashions, Motherson Sumi Wiring, and Ajanta Pharma, among others will also detail earnings on Tuesday
Glenmark Life Sciences Q2 Results: Firm posts profit rise on API boost
However, a nearly 18% rise in expenses ate into the company's core profit margin, which contracted to 29% from 30.2% a year earlier.
Q2 results: These 17 companies are likely to report loss. What should investors do?
Restaurant Brands Asia, which runs Burger King India, is seen reporting a quarterly loss of Rs 15.7 crore. While Kotak has a 'reduce' rating on the stock, Motilal has given a buy rating.
Glenmark Pharma Q4 Results: Profit declines 12.3% on higher input costs and lower demand
Glenmark Pharmaceuticals' Q4 consolidated profit before exceptional items and tax was INR3.09bn ($37.78m) for the quarter ended 31 March, down 12.3% compared to a year earlier, due to increased input costs and lower demand in the Indian drugs market. The firm posted one-time costs of INR8bn due to settlements over lawsuits in the US related to antitrust issues and consumer protection. While its sales rose 11.5%, the Indian drugs segment reported a 6.4% sales decline, accounting for 31% of its total, while North American sales grew by 15.3%.
On a path to recovery: 4 small pharma stocks with an upside potential of up to 27%
As the markets get jittery, select pharma stocks are back in focus. This tends to happen in volatile markets. Some of them are small and mid sized Indian pharma companies which are not hit by pricing pressure of the US generic market and other issues which large pharma companies are facing. The list is based on upside estimated by the analysts, with the highest potential stock coming on the top of the list.
Load More
